When are long-acting beta-agonists typically prescribed?

Long-acting beta-agonists (LABAs) are prescribed primarily as an adjunct to inhaled corticosteroids in the management of asthma and chronic obstructive pulmonary disease (COPD). This combination therapy is effective because LABAs help to relax and open the airways over an extended period, thereby improving airflow and reducing symptoms. By pairing LABAs with inhaled corticosteroids, which address inflammation, the treatment targets both the bronchospasm and the underlying inflammation associated with these respiratory conditions.

Using LABAs alone for asthma is not recommended due to the potential for increased risk of severe asthma exacerbations, especially when not combined with corticosteroids. Inhaled beta-agonists are not intended for immediate relief of acute symptoms; that role is typically filled by short-acting beta-agonists (SABAs). Additionally, while LABAs can be useful in managing exercise-induced bronchospasm, they are not prescribed solely for this purpose; instead, they serve a broader function in ongoing asthma management. This understanding highlights why prescribing LABAs as adjuncts to inhaled corticosteroids is crucial for optimal patient care.